Selective eradication of cancer displaying hyperactive Akt by exploiting the metabolic consequences of Akt activation

  1. Veronique Nogueira  Is a corresponding author
  2. Krushna Chandra Patra
  3. Nissim Hay  Is a corresponding author
  1. University of Illinois at Chicago, United States

Abstract

Akt activation in human cancers exerts chemoresistance, but pan-Akt inhibition elicits adverse consequences. We exploited the consequences of Akt-mediated mitochondrial and glucose metabolism to selectively eradicate and evade chemoresistance of prostate cancer displaying hyperactive Akt. PTEN-deficient prostate cancer cells that display hyperactivated Akt have high intracellular reactive oxygen species (ROS) levels, which are due, in part, to Akt-dependent increase of oxidative phosphorylation. High intracellular ROS levels selectively sensitize cells displaying hyperactive Akt to ROS-induced cell death enabling a therapeutic strategy combining a ROS inducer and rapamycin in PTEN-deficient prostate tumors in mouse models. This strategy elicited tumor regression, and markedly increased survival even after the treatment was stopped. By contrast, exposure to antioxidant increased prostate tumor progression. To increase glucose metabolism Akt activation phosphorylates HK2 and induced its expression. Indeed, HK2 deficiency in mouse models of Pten-deficient prostate cancer elicited a marked inhibition of tumor development and extended lifespan.

Article and author information

Author details

  1. Veronique Nogueira

    Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, United States
    For correspondence
    vnogueir@uic.edu
    Competing interests
    The authors declare that no competing interests exist.
  2. Krushna Chandra Patra

    Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Nissim Hay

    Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, United States
    For correspondence
    nhay@uic.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6245-3000

Funding

National Institutes of Health (R01AG016927)

  • Nissim Hay

VA (BX000733)

  • Nissim Hay

National Institutes of Health (R01 CA090764)

  • Nissim Hay

National Institutes of Health (R01 CA206167)

  • Nissim Hay

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Matthew G Vander Heiden, Massachusetts Institute of Technology, United States

Ethics

Animal experimentation: Animal experimentation: Mice were maintained and handled in accordance with the Animal Care Policies of the University of Illinois at Chicago and studies were approved by Animal Care and Use Committee under protocol numbers 13-036 and 14-112.

Version history

  1. Received: September 22, 2017
  2. Accepted: April 11, 2018
  3. Accepted Manuscript published: April 24, 2018 (version 1)
  4. Accepted Manuscript updated: April 25, 2018 (version 2)
  5. Version of Record published: May 31, 2018 (version 3)

Copyright

© 2018, Nogueira et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,368
    views
  • 416
    downloads
  • 32
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Veronique Nogueira
  2. Krushna Chandra Patra
  3. Nissim Hay
(2018)
Selective eradication of cancer displaying hyperactive Akt by exploiting the metabolic consequences of Akt activation
eLife 7:e32213.
https://doi.org/10.7554/eLife.32213

Share this article

https://doi.org/10.7554/eLife.32213

Further reading

    1. Cancer Biology
    Chenxi Gao, Huaibin Ge ... Jing Hu
    Research Article

    BRAFV600E mutation is a driver mutation in the serrated pathway to colorectal cancers. BRAFV600E drives tumorigenesis through constitutive downstream extracellular signal-regulated kinase (ERK) activation, but high-intensity ERK activation can also trigger tumor suppression. Whether and how oncogenic ERK signaling can be intrinsically adjusted to a ‘just-right’ level optimal for tumorigenesis remains undetermined. In this study, we found that FAK (Focal adhesion kinase) expression was reduced in BRAFV600E-mutant adenomas/polyps in mice and patients. In Vil1-Cre;BRAFLSL-V600E/+;Ptk2fl/fl mice, Fak deletion maximized BRAFV600E’s oncogenic activity and increased cecal tumor incidence to 100%. Mechanistically, our results showed that Fak loss, without jeopardizing BRAFV600E-induced ERK pathway transcriptional output, reduced EGFR (epidermal growth factor receptor)-dependent ERK phosphorylation. Reduction in ERK phosphorylation increased the level of Lgr4, promoting intestinal stemness and cecal tumor formation. Our findings show that a ‘just-right’ ERK signaling optimal for BRAFV600E-induced cecal tumor formation can be achieved via Fak loss-mediated downregulation of ERK phosphorylation.

    1. Cancer Biology
    2. Computational and Systems Biology
    Marie Breeur, George Stepaniants ... Vivian Viallon
    Research Article

    Untargeted metabolomic profiling through liquid chromatography-mass spectrometry (LC-MS) measures a vast array of metabolites within biospecimens, advancing drug development, disease diagnosis, and risk prediction. However, the low throughput of LC-MS poses a major challenge for biomarker discovery, annotation, and experimental comparison, necessitating the merging of multiple datasets. Current data pooling methods encounter practical limitations due to their vulnerability to data variations and hyperparameter dependence. Here, we introduce GromovMatcher, a flexible and user-friendly algorithm that automatically combines LC-MS datasets using optimal transport. By capitalizing on feature intensity correlation structures, GromovMatcher delivers superior alignment accuracy and robustness compared to existing approaches. This algorithm scales to thousands of features requiring minimal hyperparameter tuning. Manually curated datasets for validating alignment algorithms are limited in the field of untargeted metabolomics, and hence we develop a dataset split procedure to generate pairs of validation datasets to test the alignments produced by GromovMatcher and other methods. Applying our method to experimental patient studies of liver and pancreatic cancer, we discover shared metabolic features related to patient alcohol intake, demonstrating how GromovMatcher facilitates the search for biomarkers associated with lifestyle risk factors linked to several cancer types.